Market Research Logo

Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts

Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts

Antibiotics are drugs used to treat infections that are caused by bacteria.

The introduction of antibiotics is recognized as one of the most transformative events in medicine.

Prior to the introduction of the first antibiotics in the 1930s and 1940s, bacterial infections were often fatal, and invasive surgery was accompanied by a high risk of infectious complications.

Today, antibiotics are used routinely to treat and prevent infection.

However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself.

Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile.

And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually.

Or bioweapons like Anthrax.

Unfortunately, it is hard to discover new antibiotics.

Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs.

As a result, most novel antibiotic development is now being conducted by small biotech companies.

Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.

Current antibiotics work now, for the most part.

But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics.

The need to invest is now, so there are options when the inevitable next black death appears.

This report addresses these issues.

Specifically, it provides:

Antibiotics Overview.

Quest for Super Antibiotic Drugs.

Antibiotics Market.

Company Profiles.

In addition to 37 company profiles, the report contains 14 tables and 62 figures.


  • EXECUTIVE SUMMARY
    • Antibiotics Overview
    • Quest for Super Antibiotic Drugs
    • Antibiotics Market
    • Competitive Environment
  • INTRODUCTION
    • Methodology and Sources
    • Statistical Notes
  • ANTIBIOTICS OVERVIEW
    • Bacteria Taxonomy
    • Microbes in Context
      • Table Microbes Vs. Humans by Factor
    • Antibiotics Definition
    • Quest for Super Drugs
    • Soil Microbes
    • Antibiotic Categories
    • Gram-Positive vs. Gram-Negative Bacteria
    • Broad vs. Narrow Spectrum
    • Static vs. Cidal
    • Susceptibility, Potency and MIC
    • Bactericidal Antibiotics
    • Breakpoint
    • Efficacy and Safety
    • Mechanisms of Action
    • Antibiotic Resistance
    • Modes of Resistance
      • Table Characteristics of Antibiotics by Class
    • Resistance Is Nothing New
    • Costs of Antibiotic Resistance
    • Treatment Guidelines
      • Table Bacterial Infections by Pathogen Species, by CDC Threat Level (Urgent, Serious, Concerning), by Infections/Year (Number), by Drug-Resistant Infections (Number), by Lethal Infections (Number), by MDR Infections (Number), by G+/G-
    • Antibiotic Overuse
    • ESKAPE
    • Most Common Infections
    • Antibiotic Resistance Prevention
    • National Action Plan for Combating Antibiotic Resistant Bacteria
    • BARDA and NIAID Budgets
    • Presidential Advisory Council
    • United Kingdom Review on Antimicrobial Resistance
    • Margolis Center for Health Policy
    • GAIN Act
    • 21st Century Cures Act
    • MRSA on the Decline
    • CRE Poses an Urgent Threat
    • Failure Rate High
    • Global Problem
    • U.S. Cases
    • Carbapenems Use Increasing
    • ESBLs Pose a Serious Threat
    • New Delhi Metallo-Beta-Lactamase
    • Clostridium difficile
    • Few New Antibiotics Being Produced
    • Low NPV
    • Cost of Trials
    • New Antibiotics Hard to Discover
    • iChip
    • Five Pharma Companies Left
    • Development Now Done by Startups
    • Numerous Studies on Situation
    • Disaster Planning
    • Path Forward
    • Alternative Is Unimaginable
  • QUEST FOR SUPER ANTIBIOTIC DRUGS
    • Discovery Platform Has Collapsed
    • New Antibiotic Discovery Process
    • Rationally Improve Existing Antibiotics
    • Rediscover Old Antibiotics
    • Repurpose Old Drugs
    • Discover Untested New Chemical Diversity
    • Community for Open Antimicrobial Drug Discovery
    • Target-Based Approaches
    • Long Time-Lower Success Rates
    • Focus for New Antibiotic Drugs Well Established
    • Dearth of New Antibiotic Drug Classes
    • Dearth of New Antibiotic Drugs
    • R&D Development and Commercial Challenges
    • Modest Performance of New Antibiotics
    • Few Big Players Remain
    • New Key Initiatives
    • Growing Wave of Activity in Antibiotics
    • Activity Mostly Led by Biotechs
    • Renewed Enthusiasm
    • Antibiotics in Late Clinical Development
    • Obtaining Investments for New Antibiotics Is Difficult
    • Startups Believe They Can Find New Antibiotics
    • Antibiotics Approved in Recent Years
    • Stewardship
    • New Antibiotics That Have Received Marketing Authorization
    • Disappointing Sales Post-Launch
    • Generic Competition
    • Beta-lactamases, Cephalosporinase and Carbapenemase Inhibitors
    • New Cephalosporins
    • New Aminoglycosides
    • New Pleuromutilins
    • New Tetracyclines
    • New Macrolides
    • New Fluoroquinolones and DNA Gyrase Inhibitors
    • New Oxazolidinones
    • New Fatty Acid Biosynthesis Inhibitors
    • New Folate Biosynthesis Inhibitors
    • Defensin-Mimetic Peptides
    • Other Classes
    • Old Antibiotics with New Dosing
    • Fusidane
    • Fosfomycin
      • Table Antibiotics Currently in Clinical Development: March 2017
    • Early-Stage Molecules
    • Analogs of Existing Classes Still Difficult to Develop
    • New Oral Antibiotics for Outpatients Urgently Needed
    • New Oral Antibiotics for Children Urgently Needed
    • Government Incentives Needed
    • Options Market for Antibiotics
    • Antibiotics Prize
  • ANTIBIOTICS MARKET
    • Antibiotics Production Value
      • Table Global Antibiotics Market ($ Million): 2017-2022
    • Production Value by Class
    • Cephalosporins
    • Marcolides
    • Penicillins
    • Carbapenems
    • Tetracyclines
    • Sulfonamides
    • Aminoglycosides
    • Other Antibiotics
      • Table Global Antibiotics Market by Class ($ Million): 2017-2022
    • Production by Region
      • Table Global Antibiotics Production in U.S., EU, Rest of World ($ Million): 2017-2022
    • Consumption Volume Data
    • Antibiotic Market Volume
    • Consumption by Country
    • Class Differences by Country
    • Inappropriate Use
    • Public Health Issues
    • Applications
    • Anti-MRSA Antibiotics
      • Table MRSA Cases, I.V. MRSA Treatment Days, U.S. Market for Anti-MRSA Antibiotics by Drug and Producer ($ Million): 2017-2022
    • Cubicin
    • Zyvox
    • Teflaro
    • Tygacil
    • Vibativ
    • Dalvance
    • Other
    • Community Acquired Bacterial Pneumonia
    • Healthcare-Associated Infections Decreasing
    • Medicare Part D
      • Table 10 Most Common Antibiotics Prescribed to Medicare Part D Beneficiaries (Million Claims, $ Million): 2013
    • Competitive Environment
    • Large Pharma Exits Antibiotics
    • Biotech Enters Antibiotics
    • Antibiotic Deal Making
    • Competitors
      • Table 222 Companies Producing or Doing R&D on Antibiotics, Headquarters Country and Website: 2017
    • Market Shares
      • Table Antibiotics Production and Market Shares by Company ($ Million, %): 2016
    • Antibiotic Supply Chains
    • India and China Antibiotic Supply Chains
    • Antibiotic Pollution Issues
    • Chinese Companies
    • North China Pharmaceutical Group
    • CSPC Pharmaceutical Group/Inner Mongolia Changsheng Pharmaceuticals
    • Sinopharm WeiQida
    • Shandong Lukang Pharmaceuticals
    • Harbin Pharmaceutical Group
    • Tonglian Group
    • United Laboratories
    • Indian Companies
    • Aurobindo
    • Mylan Laboratories Ltd.
    • Dr Reddy's
    • Hetero Drugs Ltd.
    • Orchid Pharmaceuticals
  • COMPANY PROFILES
    • Achaogen Inc
    • Product Offering
    • CRE
    • Plazomicin
    • Trials
    • EPIC
    • CARE
    • Launch
    • QIDP Designation
    • BARDA
    • Pipeline
    • C-Scape
    • LpxC
    • P. aeruginosa
    • Antibacterial Monoclonal Antibodies
    • Other Monoclonal Antibody Programs
    • Intellectual Property
    • Competition
    • Financial
      • Table Achaogen Inc Income Statement ($ Thousand): 2012-2016
    • Actelion Ltd.
    • AstaZeneca plc
    • Small Molecule Unit
      • Table AstraZeneca's Small Molecule Antibiotic Products
    • Atox Bio
    • Basilea Pharmaceutica AG
    • Ceftobiprole
    • Cempra Inc
    • Solithromycin
    • Applications
    • BARDA
    • Fusidic Acid
    • ABSSSI
    • CrystalGenomics, Inc.
    • CG400549
    • Cubist Pharmaceuticals, Inc.
    • Sivextro
    • Destiny Pharma Ltd.
    • Pipeline
    • Dong Wha Pharmaceuticals
    • Durata Therapeutics, Inc.
    • Eisai Co., Ltd.
    • Furiex Pharmaceuticals, Inc.
    • GlaxoSmithKline, Plc.
    • Gepotidacin
    • Grupo Ferrer Internacional S.A.
    • Ozenoxacin
    • Insmed Incorporated
    • ARIKAYCE
    • Approvals
    • Patent
    • INS1007
    • KaloBios Pharmaceuticals, Inc.
    • Technology
    • KB001-A
    • Melinta Therapeutics, Inc.
    • Baxdela
    • Merck & Co., Inc.
      • Table Merck Revenue by Segment and Products ($ Million): 2016
    • Cubicin
    • Primaxin
    • Zerbaxa
    • Sivextro
    • MK-7655A
    • Acute Care Position
    • MerLion Pharmaceuticals Pte Ltd
    • Finafloxacin
    • MRSA
    • Intraabdominal Infections
    • Chronic Obstructive Pulmonary Disease
    • Cystic Fibrosis
    • Other Hospital and Critical Care Infections
    • Helicobacter pylori
    • MicuRx Pharmaceuticals, Inc.
    • Nabriva Therapeutics AG
    • Lefamulin
    • Osel Inc
    • LACTIN-V
    • CBM588
    • Novartis AG
    • Sandoz
    • Antibiotics
    • Otonomy, Inc.
    • Otsuka Pharmaceutical Co. Ltd.
    • Tuberculosis Effects More Than 10 Million
    • Delamanid
    • Bedaquiline
    • Paratek Phamaceuticals, Inc.
    • Pfizer Inc
    • AstraZeneca Acquisition
    • Antibiotics
      • Table Pfizer Anti-Infective U.S. and Non-U.S. Sales by Product ($ Million): 2013-2020
    • Tygacil
    • Polyphor Ltd.
    • Technology
    • Murepavadin
    • Roche Collaboration
    • Rebiotix, Inc.
    • RBX2660
    • Roche Holding AG
    • Antibiotics
    • OP0595
    • Savara Pharmaceuticals
    • Sequella, Incorporated
    • Available Markets
    • Seres Therapeutics, Inc.
    • SER-109
    • Summit, plc
    • TaiGen Biotechnology Co., Ltd.
    • TaigexynR
    • Tetraphase Pharmaceuticals, Inc.
    • Tetracycline
    • Eravacycline
    • TP-271
    • TP-6076
    • QIDP
    • Licensed from Harvard
    • BARDA
    • The Medicines Company
    • Infectious Disease Business
    • Meropenem-Vaborbactam
    • MINOCINR
    • ORBACTIVR
    • R&D
    • Theravance Biopharma Inc
    • VIBATIV
    • Competition
  • ANTIBIOTIC CLASSES
    • Aminoglycosides
    • b -Lactams
    • b -Lactam Resistance
    • Penicillins
    • Carbapenems
    • Cephalosporins
    • Fluoroquinolones
    • Lipoglycopeptides
    • Lipopeptides
    • Oxazolidinones
    • Macrolides
    • Tetracyclines
      • Table Classes of Antibiotics by Type and Generic, Brand, Target, MOA, Formulation AE
  • REGULATION
    • Food, Drug, and Cosmetic Act
    • Approval Process
    • Preclinical Studies
    • Clinical Trials
    • Marketing Approval
    • Foreign Clinical Trials
    • Approval Letter
    • Special FDA Expedited Review and Approval Programs
    • Breakthrough Therapy
    • Post-Approval Requirements
    • Section 505(b)(2)
    • Qualified Infectious Disease Product Exclusivity

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report